Quantcast

Latest Biologic Stories

2014-02-26 23:03:59

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced two senior appointments to further strengthen its global biologics business. Somerset, NJ (PRWEB) February 26, 2014 Andrew Sandford joins Catalent as Vice President, Business Development, Biologics, and will focus on growth of the company’s existing biologics offerings, including the recently completed...

2014-02-26 16:29:42

ROCKVILLE, Md., Feb. 26, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that Founder, Board member and subsidiary CEO and President, Steve H. Kanzer, has resigned from the Company, effective immediately, to return his focus to his venture capital and investment banking firms on a full-time basis....

2014-02-25 23:36:32

Gallus BioPharmaceuticals, LLC, a premier pure-play biologics contract manufacturing organization has signed a manufacturing agreement with Symphogen, A/S, a private biopharmaceutical company developing recombinant monoclonal antibody mixtures for the treatment of cancer. St. Louis, Missouri (PRWEB) February 25, 2014 Gallus BioPharmaceuticals, LLC (Gallus), a premier pure-play biologics contract manufacturing organization (CMO) has signed a manufacturing agreement with Symphogen, A/S...

2014-02-24 12:26:47

DALLAS, February 24, 2014 /PRNewswire/ -- ReportsnReports.com offers "Therapeutic Class Overview : Emergence Of Biogenerics Era In Japan - It's Time to Welcome Antibody Biosimilars of Foreign Origins Soon" and "Therapeutic Class Overview: Newer Oral Anti Androgens - Expanding Role in the treatment Paradigm of Prostate Cancer" research reports in its store. Japan biosimilar market will enter new phase of biosimilars with first 'mab' approval expected in 2014. This...

2014-02-20 04:20:55

-- More than 200 artists inspired by patients in more than 40 countries NORTH CHICAGO, Ill., Feb. 20, 2014 /PRNewswire/ -- AbbVie today announced the launch of 'Perspectives - Art, Inflammation and Me', an initiative designed to add a different dimension to the current understanding of immune-mediated inflammatory diseases (IMIDs) and their impact on patients and society. More than 100 unique artistic expressions from the initiative are being debuted at the 9th Congress of the...

2014-02-19 08:31:36

- BioMotiv Establishes Kodosil Bio to Develop Collaboration Compounds - SAN DIEGO and CLEVELAND, Feb. 19, 2014 /PRNewswire/ -- BioAtla, a global biotechnology company focused on the development of conditionally active biologics (CABs), and BioMotiv, the therapeutics accelerator for The Harrington Project for Discovery & Development, today announced that BioAtla licensed exclusive worldwide rights to BioMotiv to develop and commercialize its TH22 pathway-directed antibody compound...

2014-02-19 08:30:00

ALBANY, New York, February 19, 2014 /PRNewswire/ -- ResearchMoz.us includes new market research report "Hepatitis C Therapeutics in Major Developed Markets to 2019 [http://www.researchmoz.us/hepatitis-c-therapeutics-in-major-developed-markets-to-2019-outstanding-recent-approvals-and-late-stage-pipeline-to-transform-clinical-and-commercial-landscape-report.html ] " to its huge collection of research reports. Researchmoz presents this most up-to-date research on...

2014-02-17 23:02:51

Biosimilars Products Market report is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. (http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html) (PRWEB) February 17, 2014 The “Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) -...

2014-02-13 16:27:47

ROCKVILLE, Md., Feb. 13, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that in view of the unusual market activity in the Company's stock, the NYSE MKT (the "Exchange") has contacted the Company in accordance with its usual practice. The Company stated that its policy is not to comment on unusual market activity. About Synthetic...

2014-02-11 12:25:31

DUBLIN, February 11, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/6mkhtx/biosimilars) has announced the addition of the "Biosimilars Market by Product & Application - Global Forecast to 2018" [http://www.researchandmarkets.com/research/6mkhtx/biosimilars ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The global market is segmented on the basis of products, applications, and...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related